Most rating values will, therefore, be close to the mean but there is a high probability of one or more outlying points occurring. This will cause statistically significant, but spurious, correlations.
Taking all of this into consideration, I agree with the authors' conclusion that â€oe¿ Further research is clearly needed to substantiate these resultsâ€•. the plasma levels were within the 0.5â€"3.0 ng/ml range.
Community Mental Health
For flupenthixol: B=0.05, 95% confidence inter val= 0.038â€"0.06. 114/140 observations (81.4%) of the plasma levels were within the 0.5â€"3.0 ng/ml range.
For haloperidol: B = 0.05, 95% confidence inter val=0.02â€"0.07. 42-47 observations (89.3%) of the plasma levels were within the 0.5â€"4.0ng/ml range.
The results show that in this stable group the plasma levels are within a definite range. The vari ation of haloperidol is higher than for flupenthixol and fluphenazine.
As However, both report that a â€˜¿ too low' dosage leads in thelong term (more than one year) to a statistically greater chance of relapse. Marder em ' al(1990) showed that lower plasma levels of fluphenazine ( < I.0 ng/ ml) do indeed significantly correlate with a relapse after six or nine months. They measured the plasma level at the day ofinjection using a RIA-method and report a range ofO.5â€"3 ng/ml.
Norman et al(l987) found in a comparable group of stable out-patients on long-term fluphenazine decanoate an average plasma level for males (n =9) of 1.3 @tg/l and for females (n = 8) 1.0 @sg/l.They found no relationship between BPRS-scores and plasma levels over time.
In a preliminary analysis we found no influence of anxiolytics, anticholinergics, or sex on plasma level.
We realise that our study is methodologically weak, but the results correlate quite well with the results of the study that Marder et a! report in this journal.
Furthermore, we think that our data do support the view that in future research on relapse prevention in maintenancetherapy,more attention should be given to plasma levels, since patients receiving 20 mg or 40mg of flupenthixol or fluphenazine per week may have the same plasma level. Individual, unique, metabolic factors may playa role inthese differences. Other factors such as age,race,or co-medication might also influence the plasma levels.
We proposeforfuture studies concerning relapse prevention in maintenance therapy that plasma levels of flupenthixol of 0.5â€"3.0 ng/ml, fluphenazine 0.5â€" 3.0 ng/ml and haloperidol 1.0â€"4.0 ng/ml are studied. 
